Amedisys Inc (NASDAQ:AMED) insider Sharon Brunecz sold 1,050 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $136.28, for a total value of $143,094.00. Following the sale, the insider now owns 11,480 shares of the company’s stock, valued at approximately $1,564,494.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ:AMED traded up $3.53 during mid-day trading on Tuesday, hitting $134.64. 188,200 shares of the company traded hands, compared to its average volume of 422,774. The company has a fifty day moving average of $127.93. Amedisys Inc has a one year low of $97.38 and a one year high of $141.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.88 and a current ratio of 0.88. The company has a market cap of $4.27 billion, a price-to-earnings ratio of 37.09, a price-to-earnings-growth ratio of 2.03 and a beta of 1.42.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, July 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.24. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The business had revenue of $492.98 million during the quarter, compared to analyst estimates of $489.66 million. During the same quarter in the previous year, the company posted $1.00 earnings per share. Amedisys’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, equities research analysts expect that Amedisys Inc will post 4.11 EPS for the current fiscal year.
A number of research firms recently commented on AMED. Raymond James upped their price objective on Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a research report on Monday, July 15th. Jefferies Financial Group set a $150.00 price objective on Amedisys and gave the company a “buy” rating in a research report on Monday, July 8th. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Barclays upped their price objective on Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. Finally, Royal Bank of Canada upped their price objective on Amedisys to $150.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $135.90.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.